The Oruka Therapeutics, Inc. (NASDAQ: ORKA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, financial statements, and material agreements. As a Nasdaq-listed clinical-stage biotechnology company focused on biologic therapies for chronic skin diseases, Oruka uses its SEC filings to report key corporate, financial, and governance information related to its psoriasis and inflammatory disease programs.
Investors can review Form 8-K current reports where Oruka describes material events such as private placement financings, changes in directors and executive officers, and the terms of securities purchase agreements and registration rights agreements. These filings also document board appointments, committee roles, director compensation, and equity awards, providing detail on corporate governance and leadership transitions.
Periodic reports such as Form 10-Q and Form 10-K (when available) contain condensed consolidated financial statements, including research and development and general and administrative expenses, net losses, cash, cash equivalents, and marketable securities. For a clinical-stage company like Oruka, these filings help readers understand the level of investment in plaque psoriasis and other dermatologic programs, as well as the company’s capital position and runway assumptions.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points, such as trial-related disclosures, financing structures, and changes in share count. Users can also access information related to equity issuances and warrant terms, and track how Oruka’s capital structure evolves over time. Real-time updates from EDGAR ensure that new ORKA filings, including any future proxy statements or insider transaction reports on Form 4, appear promptly with plain-language explanations to support more efficient review.
Oruka Therapeutics, Inc. General Counsel Paul T. Quinlan exercised an employee warrant for 9,000 common shares on October 20, 2026, at an exercise price of $7.80 per share. The reported employee-warrant position following the exercise was 70,996 shares. Quinlan also sold 9,000 common shares that day in five transactions; the reported weighted-average prices ranged from $74.9007 to $79.4912 per share. The sales were made under a Rule 10b5-1 trading plan entered into on May 15, 2026.
Oruka Therapeutics, Inc. Chief Medical Officer Joana Goncalves exercised employee stock options for 3,500 common shares at $6.84 per share and employee warrants for 3,500 common shares at $7.80 per share on October 15, 2026. On the same date, she sold 7,000 common shares in five transactions, with reported weighted-average prices from $73.8894 to $77.7100 per share. The sales were effected pursuant to a Rule 10b5-1 trading plan entered into September 19, 2025.
Oruka Therapeutics, Inc. (ORKA) officer Joana Goncalves reported a proposed sale of 21,000 common shares, with an aggregate market value of $1,610,280.00; Morgan Stanley Smith Barney LLC is listed as broker. The notice states that the securities to be sold were and will be received through stock-option exercises over the next three months. It also lists sales of 7,000 shares on September 15, 2026, for $643,507.20 and 7,000 shares on August 17, 2026, for $782,882.10; both are identified as 10b5-1 sales.
Oruka Therapeutics, Inc. (ORKA) Senior Vice President, Finance Arjun Agarwal exercised options for 9,999 common shares on October 12, 2026: 8,541 shares at an exercise price of $12.50 per share and 1,458 at $34.39 per share. He also reported sales totaling 9,999 shares that day. The sales were made under a Rule 10b5-1 trading plan entered into on February 11, 2026.
Oruka Therapeutics, Inc. officer Arjun Agarwal filed notice of a proposed sale of 9,999 common shares on October 12, 2026, with an aggregate market value of $821,017.89; Morgan Stanley Smith Barney LLC is listed as broker. A separate entry lists 9,999 common shares acquired that day through exercise of stock options for cash. The notice lists 66,209,699 shares outstanding.
Oruka Therapeutics CEO Lawrence Otto Klein exercised warrants for 25,000 common shares on October 1, 2026, at an exercise price of $7.80 per share. On the same date, he sold 25,000 shares in three transactions: 16,246 at a weighted-average price of $83.3979, 8,554 at $84.0256, and 200 at $84.7800. The sales were made under a Rule 10b5-1 trading plan entered into May 14, 2026. His reported position following the warrant transaction was 1,528,513 shares.
Oruka Therapeutics, Inc. lists a notice by Lawrence Klein for the proposed sale of 25,000 common shares, with an aggregate market value of $2,082,250.00 and an approximate sale date of October 1, 2026. The securities information table names Morgan Stanley Smith Barney LLC and NASDAQ.
The notice also lists 25,000 shares acquired from the issuer through stock-option exercise for cash on October 1, 2026. Earlier sales listed for the prior three months include 75,000 shares on September 1, 2026, and 2,452 shares on September 15, 2026.
Oruka Therapeutics, Inc. (ORKA) reported that Senior Vice President, Finance Arjun Agarwal sold 533 shares of common stock on September 21, 2026 at $95.75 per share in an open-market or private transaction. After this sale, he held 14,219 shares directly. The transaction was effected under a Rule 10b5-1 trading plan entered into on February 11, 2026.
Oruka Therapeutics, Inc. (ORKA) reported that its General Counsel, Paul T. Quinlan, exercised employee warrants for 10,000 shares of common stock at an exercise price of $7.80 per share on September 21, 2026. The 10,000 resulting common shares were then sold in multiple open-market transactions the same day at weighted average prices in the low-to-mid $90s per share, pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026. Following the exercise, Quinlan continues to hold 79,996 employee warrant shares at a $7.80 exercise price expiring on July 14, 2034.
Oruka Therapeutics, Inc. (ORKA) has an officer, Arjun Agarwal, filing a notice under Rule 144 for a planned sale of common stock. The notice covers 533 shares, with an aggregate market value of $50,613.68 and cites 66,209,699 shares outstanding, with sales expected around September 21, 2026. The shares come from Restricted Stock Units acquired on September 14, 2026. The filing also lists several prior sales over the past three months, including transactions made pursuant to a Rule 10b5-1 trading plan.